Ensysce Biosciences (ENSC) Institutional Ownership → Better than Bitcoin? The Biotech Stock with 46,751% Potential (From Behind the Markets) (Ad) Free ENSC Stock Alerts $0.58 +0.04 (+7.35%) (As of 04/26/2024 ET) Add Compare Share Share OwnershipStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Institutional Ownership Changes (13F Filings) for Ensysce Biosciences (NASDAQ:ENSC)CurrentInstitutional OwnershipPercentage5.63%Number ofInstitutional Buyers(last 12 months)2TotalInstitutional Inflows(last 12 months)$849.77KNumber ofInstitutional Sellers(last 12 months)1TotalInstitutional Outflows(last 12 months)$310.95K Get ENSC Insider Trade Alerts Want to know when executives and insiders are buying or selling Ensysce Biosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data ENSC Institutional Buying and Selling by Quarter Ad Behind the MarketsBetter than Bitcoin? The Biotech Stock with 46,751% Potential4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.Get the name of the stock here >>> Ensysce Biosciences Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails11/15/2023Sabby Management LLC96,973$134K0.1%-69.9%3.079% 8/14/2023Anson Funds Management LP36,261$65K0.0%N/A2.833% 5/1/2023Virtu Financial LLC13,433$65K0.0%N/A1.049% (Data available from 1/1/2016 forward) ENSC Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of ENSC shares? During the previous two years, the following institutional investors and hedge funds held shares of Ensysce Biosciences shares: Sabby Management LLC ($134K), and Anson Funds Management LP ($65K), Virtu Financial LLC ($65K).Learn more on ENSC's institutional investors. What percentage of Ensysce Biosciences stock is owned by institutional investors? 5.63% of Ensysce Biosciences stock is owned by institutional investors. Learn more on ENSC's institutional investor holdings. Which institutional investors have been buying Ensysce Biosciences stock? The following institutional investors have purchased Ensysce Biosciences stock in the last 24 months: Anson Funds Management LP ($36.26K), and Virtu Financial LLC ($13.43K). How much institutional buying is happening at Ensysce Biosciences? Institutional investors have bought a total of 49,694 shares in the last 24 months. This purchase volume represents approximately $849.77K in transactions. Which Ensysce Biosciences major shareholders have been selling company stock? The following institutional investors have sold Ensysce Biosciences stock in the last 24 months: Sabby Management LLC ($225.33K). How much institutional selling is happening at Ensysce Biosciences? Institutional investors have sold a total of 225,325 shares in the last 24 months. This volume of shares sold represents approximately $310.95K in transactions. Related Companies: KZIA Major Shareholders ARTL Major Shareholders PTPI Major Shareholders PXMD Major Shareholders LIPO Major Shareholders SNGX Major Shareholders GNPX Major Shareholders PCSA Major Shareholders DRUG Major Shareholders ZVSA Major Shareholders This page (NASDAQ:ENSC) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchJeff Bezos Just Humiliated Elon MuskInvestorPlaceBitcoin Rockets To Record High But Buy THIS InsteadParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ensysce Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
